Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation

Overview

Journal Fed Pract

Specialty Health Services

Date 2019 Feb 16

PMID 30766309

Authors

Mohammed Quader

Luke G Wolfe

Gundars Katlaps

Neil Lewis

Vigneshwar Kasirajan

Affiliations

Soon will be listed here.

Abstract

This study found significant improvements in heart transplant outcomes and survival in patients with hepatitis C virus.

References

Alter M, Nainan O, McQuillan G, Gao F, Moyer L, Kaslow R . The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8):556-62. DOI: 10.1056/NEJM199908193410802. View

Pol S, Samuel D, Cadranel J, Legendre C, Bismuth H, Brechot C . Hepatitis and solid organ transplantation. Transplant Proc. 2000; 32(2):454-7. DOI: 10.1016/s0041-1345(00)00816-2. View

Di Bisceglie A . Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000; 31(4):1014-8. DOI: 10.1053/he.2000.5762. View

Castella M, Tenderich G, Koerner M, Arusoglu L, El-Banayosy A, Schulz U . Outcome of heart transplantation in patients previously infected with hepatitis C virus. J Heart Lung Transplant. 2001; 20(5):595-8. DOI: 10.1016/s1053-2498(00)00198-4. View

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales Jr F . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. DOI: 10.1056/NEJMoa020047. View

Thomas R, Brems J, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel D . Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003; 9(9):905-15. DOI: 10.1053/jlts.2003.50166. View

Haji S, Starling R, Avery R, Mawhorter S, Tuzcu E, Schoenhagen P . Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004; 23(3):277-83. DOI: 10.1016/S1053-2498(03)00148-7. View

Hoofnagle J, Seeff L . Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006; 355(23):2444-51. DOI: 10.1056/NEJMct061675. View

10.

Cano O, Almenar L, Martinez-Dolz L, Moro J, Izquierdo M, Aguero J . Course of patients with chronic hepatitis C virus infection undergoing heart transplantation. Transplant Proc. 2007; 39(7):2353-4. DOI: 10.1016/j.transproceed.2007.07.067. View

11.

Davis G, Alter M, El-Serag H, Poynard T, Jennings L . Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2009; 138(2):513-21, 521.e1-6. DOI: 10.1053/j.gastro.2009.09.067. View

12.

Fong T, Hou L, Hutchinson I, Cicciarelli J, Cho Y . Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009; 88(9):1137-41. DOI: 10.1097/TP.0b013e3181bd3e59. View

13.

Shafii A, Su J, Smedira N, Navia J, Taylor D, Starling R . The effect of recipient hepatitis C virus infection on outcomes following heart transplantation. Transplant Proc. 2010; 42(5):1784-7. DOI: 10.1016/j.transproceed.2009.12.061. View

14.

Rosen H . Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011; 364(25):2429-38. DOI: 10.1056/NEJMcp1006613. View

15.

Lee I, Localio R, Brensinger C, Blumberg E, Lautenbach E, Gasink L . Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant. 2011; 30(11):1266-74. PMC: 3223534. DOI: 10.1016/j.healun.2011.06.003. View

16.

Everson G, Terrault N, Lok A, Rodrigo D, Brown Jr R, Saab S . A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2012; 57(5):1752-62. PMC: 3510348. DOI: 10.1002/hep.25976. View

17.

Younossi Z, Stepanova M, Nader F, Younossi Z, Elsheikh E . Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013; 37(6):647-52. DOI: 10.1111/apt.12234. View

18.

Lund L, Edwards L, Kucheryavaya A, Dipchand A, Benden C, Christie J . The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. J Heart Lung Transplant. 2013; 32(10):951-64. DOI: 10.1016/j.healun.2013.08.006. View

19.

Razavi H, Waked I, Sarrazin C, Myers R, Idilman R, Calinas F . The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014; 21 Suppl 1:34-59. DOI: 10.1111/jvh.12248. View

20.

Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K . ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-82. DOI: 10.1056/NEJMoa1402869. View